Back to Search
Start Over
199P Impact of baseline tumour burden on outcomes in EMERALD-1: A phase III study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in embolisation-eligible unresectable hepatocellular carcinoma (uHCC).
- Source :
-
Annals of Oncology . 2024 Supplement 4, Vol. 35, pS1480-S1480. 1p. - Publication Year :
- 2024
- Subjects :
- *HEPATOCELLULAR carcinoma
*BEVACIZUMAB
*TUMORS
Subjects
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 35
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 181112440
- Full Text :
- https://doi.org/10.1016/j.annonc.2024.10.220